Navigation Links
ManHunt2 Video Game: Blasted for Linking Mental Illness to Violence; Retailers Asked Not to Sell Based on Public Health Concern
Date:11/1/2007

ARLINGTON, Va., Nov. 1 /PRNewswire-USNewswire/ -- The National Alliance on Mental Illness (NAMI) today condemned the controversial video game Manhunt2 based on its irresponsible, stereotyped portrayal of people with mental illnesses, asking that it be recalled or modified, or that retailers decline to sell the game. NAMI executive director Mike Fitzpatrick issued the following statement:

"NAMI asks Rockstar Games to recall or further modify the videogame Manhunt2 due to its irresponsible, stereotyped portrayal of mental illness. We also ask retailers to be responsible in responding to public health concerns.

Even though some people may consider Manhunt2 to be only a game, it unfortunately perpetuates and reinforces cruel, inaccurate perceptions that people who live with mental illnesses are violent. The U.S. Surgeon General has condemned such stigmatization, identifying fear of stigma as a major barrier to people getting help when they need it. The overall contribution of mental illnesses to violence in society is exceptionally small. In fact, people living with mental illness are far more likely to be victims of violence.

Released on Halloween, Manhunt2 enables players to assume the role of a patient fighting to escape from the "Dixmor Asylum for the Criminally Insane." The patient uses a variety of sickening techniques to torture and kill security offices and others in his way.

Manhunt2 initially received an "Adults Only" rating for players ages 18 and older in the United States. This rating would have limited the game's market; several major retailers will not sell games with that rating. Rockstar made some small changes to the game, including the removal of a graphic scene with castration, and received a new rating of "Mature" for players ages 17 and older. The British Board of Film Classification was not satisfied with the changes and citing the game's "unremitting bleakness" and "casual sadism," has banned the game in the Uni
'/>"/>

SOURCE NAMI
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Cut down TV and video games and you have less aggressive children.
2. Parents Should Beware of Violent Video Games
3. Children’s obesity linked to video game
4. Poland: Parental warning systems are likely to be adopted in video games.
5. Video Games, The Latest Craze Of American Adults
6. Interactive Video, Better Teaching Aid For Toddlers
7. Video Games Reduces Surgical Errors – A Stud
8. Fun And Cure With Video Games
9. Stroke Rehabilitation Through Modified Video Games
10. Videoconferencing, an impetus to Pediatric Oncology
11. Free Online Educational Videos for People with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Pharmacy Technician Employment Increasing Up to 32% By 2016 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 1EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 2EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 3Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 1Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 2Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 3New Fastrack Technology Improves Productivity 55477 1New Fastrack Technology Improves Productivity 55477 2New Fastrack Technology Improves Productivity 55477 3
Other Medicine Technology:Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 2Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 4Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 5Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 6Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 7Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 8Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 9Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 2Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 3Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 4